Abstract

Objective: To evaluate the effects of canagliflozin and zinc sulphate on diabetic dyslipidemia after treating a streptozotocin-induced diabetes rat model (type-2 diabetes).
Methodology: This in vivo study was conducted in the Department of Pharmacology, King Edward Medical University, Lahore, Pakistan. In total, 48 male Sprague Dawley rats were divided equally to form six groups. All received a high-fatty diet during experimental study. Groups A and B were labelled as the normal and disease control. On day 22, diabetes was induced in Groups B, C, D, E, and F with 35 mg/kg streptozotocin, administered intraperitoneally as single dose. After confirming diabetes, the animals were treated orally for four weeks according to their groups with or without full dose (10 mg/kg/day) and half dose of canagliflozin (5mg /kg/day), alone or together with zinc sulphate (30 mg/kg/day or 15m g/k/day). Lipid profile (serum cholesterol, serum triglycerides, serum LDL and HDL) were carried out in weeks 0, 4, and 8.
Results: The combination therapy was found to be more effective as manifested by significant lowering of the values of these biochemical parameters after the treatment.
Conclusion: Combination therapy exerted a better effect on diabetic dyslipidemia as compared to the individual treatments.

Key words: Canagliflozin, diabetes mellitus, dyslipidemia, lipid profile.